65.56
-0.69 (-1.05%)
| Penutupan Terdahulu | 66.25 |
| Buka | 65.86 |
| Jumlah Dagangan | 153,963 |
| Purata Dagangan (3B) | 1,021,662 |
| Modal Pasaran | 5,782,113,280 |
| Harga / Jualan (P/S) | 955.26 |
| Harga / Buku (P/B) | 4.93 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 7 Aug 2026 |
| Margin Operasi (TTM) | -81,161.54% |
| EPS Cair (TTM) | -1.50 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -90.20% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.15% |
| Nisbah Semasa (MRQ) | 30.97 |
| Aliran Tunai Operasi (OCF TTM) | -81.98 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -57.18 M |
| Pulangan Atas Aset (ROA TTM) | -12.85% |
| Pulangan Atas Ekuiti (ROE TTM) | -16.58% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | CG Oncology, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | -3.0 |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | 0.10 |
|
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 1.17% |
| % Dimiliki oleh Institusi | 105.34% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Decheng Capital Llc | 31 Mar 2026 | 6,371,669 |
| Foresite Capital Management Vi Llc | 31 Mar 2026 | 2,221,474 |
| Seven Fleet Capital Management Lp | 31 Mar 2026 | 1,515,151 |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| MULAY JAMES | - | 59.55 | -1,964 | -116,956 |
| Jumlah Keseluruhan Kuantiti Bersih | -1,964 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -116,956 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 59.55 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| MULAY JAMES | Pengarah | 15 Jun 2026 | Jual automatik (-) | 1,964 | 59.55 | 116,956 |
| MULAY JAMES | Pengarah | 15 Jun 2026 | Pelaksanaan pilihan | 1,964 | - | - |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |